April 15, 2019 / 8:16 PM / 2 months ago

BRIEF-Novartis Announces FDA Filing Acceptance & Priority Review Of Brolucizumab For Patients With Wet AMD

April 15 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF BROLUCIZUMAB (RTH258) FOR PATIENTS WITH WET AMD

* NOVARTIS AG - USED A PRIORITY REVIEW VOUCHER TO EXPEDITE REVIEW OF BROLUCIZUMAB IN U.S. AND, IF APPROVED BY FDA, ANTICIPATES LAUNCHING BY END OF 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below